Surgical Remission of Cushing’s Disease Tied to New Autoimmune Conditions
Development of autoimmune disease was more common in patients with surgical remission of Cushing’s disease than in those with surgically treated nonfunctioning pituitary adenomas (NFPAs), according to a retrospective matched cohort study. At 3 years after surgery, 10.4% of patients with Cushing’s disease developed new-onset autoimmune disease compared with 1.6% of those with NFPAs (HR […]
Antidepressant Maintenance No Help for Bipolar I Depressive Episode
Continuing adjunctive antidepressant treatment for up to a year following remission of an acute depressive episode in patients with bipolar I disorder showed no significant benefit for preventing relapse, a randomized trial showed. At 52 weeks, 31% of patients treated with maintenance escitalopram (Lexapro) or bupropion XL (Wellbutrin XL) for that duration of time experienced […]
Mirikizumab Benefit in UC Extends Into Maintenance Phase
The investigational monoclonal antibody mirikizumab was more effective in inducing and maintaining clinical remission in patients with moderate to severe ulcerative colitis (UC) compared with placebo, according to two phase III randomized trials. Among over 1,200 patients in the LUCENT-1 induction trial, 24.2% of those who received mirikizumab experienced clinical remission at week 12 compared […]
Intermittent fasting may reverse type 2 diabetes, according to study: Study finds people with diabetes who fast intermittently may no longer need medication
After an intermittent fasting diet intervention, patients achieved complete diabetes remission, defined as an HbA1c (average blood sugar) level of less than 6.5% at least one year after stopping diabetes medication, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Intermittent fasting diets have become popular in recent […]
Many Severe Asthma Patients Achieve Remission on Biologics
PHOENIX — Biologic medications sent severe asthma into remission in a substantial proportion of patients, according to a study presented here at the annual meeting of the American Academy of Allergy, Asthma & Immunology. About 35% of 908 patients who took biologic treatments for at least 12 months were able to achieve remission status, reported […]
Two Ulcerative Colitis Biologics: Same Clinical Difference?
While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in corticosteroid-free clinical remission as well as endoscopic remission, a post-hoc analysis found. At 1 year, a similar percentage of ulcerative colitis patients reached clinical remission from infliximab and vedolizumab (39.9% vs […]